C erebral microbleeds (CMB) are subclinical markers of risk of stroke, dementia, and cognitive impairment.
Results
CMBs were observed in 8.8% of participants; 62% had a single CMB and 63% were lobar. Sample characteristics related to the primary analysis are presented in Table 1 , and results of the primary analyses for vascular risk factors previously reported to be related to CMB risk and for medication use are presented in Table 2 . Complete sample characteristics and primary analyses results are shown in Tables I and III in the onlineonly Data Supplement, respectively. Increased age was a significant predictor of CMB across all locations (P<0.001). Male sex was related to the presence of any CMB and lobar CMB alone (P<0.001). Hypertension was associated with all and 
Discussion
We confirmed that older age, male sex, low total cholesterol level, APOE status, and statin use were each associated with higher odds of CMB presence, with differential patterns of associations observed depending on the location of the CMB. None of the other risk factors studied were related to risk of CMB, suggesting that vascular risk factors besides hypertension and very low lipid levels may not play a major role in hemorrhage-prone cerebral small vessel disease. Although the association of serum cholesterol to risk of clinical intracerebral hemorrhage is controversial, 8, 9 our findings, suggest that very low total cholesterol levels are related to risk of CMB, which concurs with a previous report from the Rotterdam study. 6 We observed an association of antiplatelet therapy with deep and mixed CMB. Previous population-based studies have related antiplatelet therapy to CMB in any location, with slightly stronger associations for lobar CMB. 10 In contrast to our previous report, 7 we now use a larger sample and found that APOE ε4 was associated with strictly lobar CMB, 11 supporting the hypothesis that cerebral amyloid angiopathy is the predominant vascular pathology underlying lobar CMBs. 1 We observed a novel association of statin use with CMB presence, even after adjusting for potential confounders and without significant interactions with antithrombotic medication use, lipid levels, or inflammatory markers (online-only Data Supplement). Only 1 previous study, restricted to patients with intracerebral hemorrhage, has reported an increased risk of deep CMB with statin use although some have related statin use with increased risk of clinical intracerebral hemorrhage. 4, 12 Statins may increase the risk of CMB by mechanisms other than lipid lowering, such as selective inhibition of platelet-G-coupled α-thrombin protease-associated receptor-1, a cell bound receptor that links platelet activation and thrombin formation. 13 In our study, we cannot exclude bias by indication. Our cross-sectional design limits our ability to examine whether the observed associations are causal.
Conclusions
We report, for the first time in a community-based study, an association of statin use with the risk of CMB that does not seem to be explained by the concomitant use of other medications or by very low cholesterol levels. However, our study is hypothesis generating, needs confirmation, and certainly does not negate the benefits of statin use in prevention of ischemic cardiovascular events.
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Supplemental Methods

Study Sample
Framingham Original cohort participants attended either exam cycle 26 th or 28 th , and Offspring cohort participants attended exam cycle 7 th or 8 th . Sample selection is outlined in figure 1 . A total of 50.6% of all participants who were alive and attended these examinations underwent brain MRI with GRE T2*GRE sequences allowing CMB detection.
Exclusion criteria for the present study included refusal or contraindication for MRI (pacemaker or other implantable devices, metallic foreign body, claustrophobia), scans with significant artifacts precluding CMB assessment, and other neurological conditions that could affect brain MRI measurements (head trauma, multiple sclerosis, brain tumor). After these exclusions, a total of 136 Original and 1829 Offspring cohort participants were available for the present study (total sample size n=1965). Persons who underwent brain MRI have been previously shown to be healthier than those who did not. After MRI acquisition, data were analyzed using a custom-designed image analysis package, QUANTA 2 written for the Linux operating system. All analyses were done blind to the subject's demographic and clinical characteristics.
CMB definition
The outcome of interest was presence or absence of any CMB and CMB classified according to anatomical brain location. CMB were defined using standard criteria recently published 2 as rounded or ovoid hypointense lesions on T2*-GRE weighted sequence measuring 10mm or less in diameter and surrounded by brain parenchyma over at least half the circumference of the lesion. The presence, number and location of CMB were determined.
CMB detection reliability measures and grouping
All the scans were read by a single investigator (JRR) blinded to the subjects' demographic and clinical information. The intra-rater reliability based on blinded reading of 200 scans on two separate occasions was excellent (kappa statistic 0.78). Inter-rater reliability comparing two independent readers (JRR, SMR/AV) in a subset of 200 scans was excellent (Kappa 0.78). Scans with single CMB were reviewed by two readers (JRR, AV) and the status of lesions identified as possible CMB with conflicting interpretation by the individual readers, was decided on by consensus.
CMB location in the brain was classified into 4 groups based on assumed pathophysiology (cerebral amyloid angiopathy [CAA] and hypertensive vasculopathy). The first group, "any CMB" included participants with CMB in any brain location, deep, lobar, and/or both. The second group, "lobar only", included participants with CMB in the cortex and subcortical white matter in cerebral hemispheres only. The third group, "deep only", included those with CMB in deep regions (basal ganglia, thalamus, white matter of the internal and external capsules, brainstem and cerebellum). The fourth group, "deep and mixed", included participants who had CMB in deep regions (as in the third group) in addition to participants with CMB in mixed location (i.e. lobar and deep regions).
Vascular risk factors
Systolic and diastolic blood pressures were each taken as the average of the Framingham clinic physician's two measurements. Blood pressure was evaluated as a three level variable based on cut-points defined by the JNC-7 classification, but ignoring treatment status, as being in the 'normal' (SBP <120mm Hg and DBP <80mm Hg), 'prehypertension' (SBP between 120-139mm Hg and/or DBP between 80-89mm Hg), or 'hypertension' (SBP ≥140mm Hg and/or DBP ≥90mm Hg) range. Hypertension was also evaluated using the JNC-7 criteria, which includes medication use (SBP ≥140 mm Hg or DBP≥90 mm Hg or use of antihypertensive medications). Current cigarette smoking was defined as self-reported use in the year prior to the examination. Total and high-density lipoprotein (HDL) cholesterol, and triglycerides were measured on fasting specimens in the Offspring cohort, and random samples in the Original cohort. LDL-cholesterol concentrations were calculated according to the formula 3 LDL= (total cholesterol minus[HDL-cholesterol plus-(triglycerides/5)) in participants with triglyceride levels below 400mg/dL, and missing in those with higher levels. Cholesterol levels were considered both as continuous variables and dichotomized into very low versus higher (<10 th percentile versus ≥10 th percentile), given the previously reported association of very low cholesterol levels with CMB. 4 We used the average of lipid levels corresponding to a period of ~12 years prior to the baseline examination to reflect long term lipid levels. Diabetes was defined as a random blood glucose ≥200 mg/dl (≥11.1 mmol/L) for the Original cohort, fasting glucose ≥126mg/dl (≥7 mmol/L) for the Offspring cohort or use of insulin or oral hypoglycemic medications (for either cohort). Fasting plasma glucose and insulin levels were measured to calculate the homeostasis model assessment insulin resistance index (HOMA-IR) using the formula (fasting insulin x fasting glucose)/22.5. The presence of the metabolic syndrome was established using the ATP III definition criteria 5 (presence of at least three of the following: waist circumference >40 inches (102 cm) for men, >35inches (88cm) for women; HDL cholesterol <40 mg/dL for men or< 50mg/dL for women; Triglyceride level ≥150 mg/dL; high blood pressure (SBP >130 mm Hg or DBP >85 mm Hg or being on antihypertensive treatment; fasting plasma glucose>110 mg/dL or being on diabetes treatment). Body mass index was defined as weight divided by height 2 (in kilograms per meter squared). Obesity was defined as BMI ≥30kg/m2. Waist circumference was measured at the level of the umbilicus and recorded to the nearest quarter inch by trained clinic staff.
Secondary prevention treatments
Medication use was assessed by self-report during interview at the corresponding examination cycle closest to MRI. Medications used for secondary prevention included antihypertensive agents, antiplatelet agents, anticoagulant therapies, lipid lowering agents in general and statins in particular.
APOE Status
Genotyping was done using previously described methods and APOE status was available in 1,928 participants (98%). 6 We dichotomized APOE genotype as any ε4 allele versus none, based on previously reported stronger association of this allele with risk of lobar CMB 4 reflecting CAA.
Supplemental Results and discussion
Baseline characteristics of the sample stratified by cohort are shown in Table 1 . The cohorts were different in several characteristics, thus all analyses were further adjusted for cohort effect and results were largely unchanged. The prevalence of CMB increased with age (Table 2) reaching 18% in those aged 80 years or older, and was higher in men than women, with an overall prevalence of 11.1% versus 6.9% respectively.
All results of the primary analyses are presented in Table 3 . Lipid lowering treatment (statins account for 80%) was related to any CMB (p<0.01) and was associated with more than a 2-fold increased odds of having deep only (p<0.05), and deep + mixed CMB (p<0.01). Hypertension treatment was related to higher odds of any CMB (P<0.05) deep only (p<0.05) and deep + mixed CMB (p<0.01).
In multivariable adjusted analyses (Table 4) , stage 1 hypertension remained a significant predictor of deep + mixed-type CMB (p<0.05) as did hypertension treatment (p<0.05). Statin use was related to higher odds of CMB (p<0.05). Average total cholesterol <10 th percentile remained associated with both overall CMB (p<0.05) and with lobar CMB (p<0.05) even after adjustment for medication use and hypertension. All lipid lowering treatment and antiplatelet use were no longer associated with CMB presence.
In order to further investigate the association between statin use and CMB, we conducted secondary analyses first excluding participants with total cholesterol levels below the 10 th percentile at their index exam, and second relating statin use to CMB burden as represented by number of any CMB. In the first analysis, after adjustment for age, sex, time interval, hypertension, antiplatelet use, anticoagulant use, and prevalent CVD, statin use remained a significant predictor of any CMB (p<0.05). In the second, age and sex-adjusted analysis relating statin use to CMB number, statin use was related to significantly higher odds of having 2 or more CMB (n=66) (OR 2.21 (1.33-3.68), p<0.002), and to borderline increased odds of having 3 or more CMB, perhaps due to the smaller sample size (n=39) (OR 1.83, 95% CI 0.96-3.49, p=0.07). After adjusting for other vascular risk factors, the relation of statin use and CMB number remained significant among participants with 2 or more CMB (OR 1.76, 95% CI 1.02-3.04, p<0.05).
Discussion
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The prevalence of CMB observed in the present study is in line with reported prevalence in other studies using similar techniques for CMB detection, when considering similar age groups. For instance, a prevalence of 11.1% was reported in the AGES Reykjavik study (mean age 77years) 7 and we observed a comparable CMB prevalence of 15.9% in the 70 to 79 year age group. However, we observed CMBs in a lower proportion of participants compared to the Rotterdam study (250/1062, mean age 69.2 years), likely due to the different MRI protocol used in the latter study. CMB detection is affected by parameters such as the MRI protocol used and magnetic field strength used. We cannot exclude under-detection of CMB in our sample, but we have used an MRI technique and field strength that are widely utilized in clinical practice, followed recent guidelines for CMB detection and demonstrate good reproducibility. Further, under ascertainment of CMB in our sample is more likely to bias the results towards the null hypothesis, rather than create spurious associations. The regional distribution of CMB was similar to that described in prior reports, with a predominance of lobar over deep CMB. 4, 7 In regards to the relation of statin use and CMB presence, it may be argued that the association observed is related to the lipid lowering effect of statins or the concomitant use of other medications increasing hemorrhagic risk among statin users. We investigated this possibility by adjusting for cholesterol levels and in stratified analysis excluding participants with very low lipid levels below the 10 th percentile which did not attenuate the association. We investigated potential interaction such as with antithrombotic medications and lipid levels, finding that statin use may independently modify the risk for CMB, and the stronger association of statin use with a larger number of CMB may be relevant. We also evaluated if the effect is mediated by inflammation, given the role of statins in modulating the systemic and vascular inflammatory response. There was no effect modification of this association by markers of systemic inflammation in general (C-reactive protein), 8 and vascular inflammation in particular (LpPLA2 levels). 9 In regards to the relation of lipid levels and CMB presence, we used averaged lipid levels to reflect the level of exposure over a period of 12 years and found that participants with very low total cholesterol levels, i.e. lower than 10 th percentile (162mg/dL), have an increased risk of any CMB and lobar location CMB after adjusting for confounders. Baseline total and LDL cholesterol levels <10 th percentile were related to risk of CMB in deep and mixed location, but the association was no longer significant after adjustment for vascular covariates (data not shown). Our study is limited as the blood sample was not fasting for participants in the original cohort and various lipid components, especially triglycerides, may vary in the fasting state, although adjustment for cohort effect did not alter the results.
Of note, in this report we observed an association of APOE status with CMB presence, contrasting with a previous CMB report from the Framingham Heart Study. The difference is likely due to the much smaller sample used in the initial report and is consistent with other population based studies. 10 Although the APOEε4 allele has been postulated to modify lipid levels, the effect of APOE in CMB risk is unlikely to be solely mediated by lipid levels since our results did not change with adjustment for cholesterol levels. Further, the APOEε4 genotype is associated with higher rather than lower cholesterol levels.
In summary, we report an updated prevalence of CMB in the community-based, strokeand dementia-free, middle-aged to older sample of Framingham study participants across two generations. The mean age of our sample is younger than in two prior reports from population cohorts, and the prevalence we observed was intermediate. The relation of various vascular risk factors and CMB presence observed support the notion of a different pathophysiology for CMB depending on their location in the brain. We found a novel association of statin use and CMB presence that merits replication. This study expands our understanding of CMB pathophysiology, and will provide the basis for future studies exploring genetic, vascular and biomarker associations, and the clinical correlates of prevalent and incident CMB in the Framingham study. 
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